Clinical Trials Directory

Trials / Completed

CompletedNCT04286607

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
333 (actual)
Sponsor
Arcutis Biotherapeutics, Inc. · Industry
Sex
All
Age
2 Years – 11 Years
Healthy volunteers
Not accepted

Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

Detailed description

This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis

Conditions

Interventions

TypeNameDescription
DRUGTopical roflumilastActive treatment

Timeline

Start date
2020-02-12
Primary completion
2024-01-22
Completion
2024-01-22
First posted
2020-02-27
Last updated
2025-01-07

Locations

85 sites across 3 countries: United States, Canada, Dominican Republic

Regulatory

Source: ClinicalTrials.gov record NCT04286607. Inclusion in this directory is not an endorsement.

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (NCT04286607) · Clinical Trials Directory